Video Guide

Catalyst Database

Chronological list of catalyst events. Click "See Drug Details" to view detailed info in our AmpCard. Use the Sort options or search box below (e.g. "Phase 2") to filter the catalyst results.

Sort Table By:

Ticker

Catalyst Date

Reset Search

Ticker

Drug | Disease (links)

Stage (next event)

Catalyst Date

NVS

Phase 3

Atrasentan

IgA Nephropathy

Q1 2026

ALIGN trial. 08/11/23- Acquisition closed—acquired asset from KDNY. 11/30/23- Topline 36-wk data , met primary endpoint. Submit application in H1 2024 for accelerated approval. Study continues w/ final readout in Q1 2026. 5/25/24 Results from a pre-specified interim analysis at ERA '24

Data readout

ATAI

Phase 2

VLS-01 (buccal film DMT)

TRD (Treatment-resistant depression)

Q1 2026

Elumina trial. Q4 2024- Dosed first patient in Ph2 Elumina trial; topline data in Q1 2026.

Data readout

ATAI

Phase 2

EMP-01 (3,4-methylenedioxy-methamphetamine [MDMA] derivative)

Social Anxiety Disorder (SAD)

Q1 2026

1/2/24- Positive Ph1 topline results. Q4 2024- Initiated Ph2 trial; topline data in Q1 2026.

Data readout

PTN

Phase 2

Bremelanotide + PDE5i

Erectile dysfunction

H2 2026

10/1/24 - PK study to start in Q1 2025 and Ph2/3 study in H2 2025 w/ topline data in H1 '26.

Data readout

ARGX

Phase 1

ARGX-121

IgA Inhibitor

H1 2026

2/27/25- Ph1 trial ongoing, topline results expected in H1 2026.

Data readout

ARGX

Phase 1

ARGX-213

FcRn Inhibitor

H1 2026

2/27/25- Ph1 trial ongoing, topline results expected in H1 2026.

Data readout

ARGX

Phase 2a

ARGX -119

Amyotrophic Lateral Sclerosis (ALS)

H1 2026

Ph1 trial ongoing. Ph1b/2a to start by end of 2024. 3/7/25- Trial presentation at AAN '25 on April 8, 2025. 2/27/25- Ph2a topline data in H1 2026.

Data readout

PRAX

Phase 2

PRAX-562

Developmental and epileptic encephalopathies (DEE)

H1 2026

EMBOLD study w/ two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients. 5/22/24 Study completed in pediatric patients. 9/3/24- Topline data reported. Registrational phase initiated. 11/6/24- EMERALD (registrational study) to commence in H1 2025. 2nd cohort to enroll 80 pts w/ topline data in H1 2026.

Data readout

AKRO

Phase 3

Efruxifermin (FGF-21 mimetic)

Compensated cirrhosis (F4) due to MASH

H1 2026

SYNCHRONY Outcomes trial. 6/11/24- Initiated trial. 9/9/24- First patient dosed. 1/13/25- Results expected in H1 2026.

Data readout

DMAC

Phase 2/3

DM199 (KLK1 protein)

AIS (Acute Ischemic Stroke)

H1 2026

ReMEDy2 trial. 6/21/23- Lifted clinical hold. 4/17/24- First patient dosed. 11/13/24- To submit amended SAP to FDA. 3/17/25- Enrollment ongoing. Interim analysis for sample size re-estimation on first 200 participants in H1 2026.

Data readout

Amp Volatility is calculated based off of options pricing with expiration after event.
Last Calculated: 03/13/20